Wilson's Disease with Cirrhosis: What to Do When Chelating Agent Switching Has Not Worked

This protocol covers a high-severity presentation of Wilson's disease — patients with significant liver fibrosis, cirrhosis, liver failure, or haemolysis in whom a prior switch between chelating agents has failed to achieve the required liver recovery targets.

Clinical Scenario

Patients with Wilson's disease who have features of significant liver fibrosis, cirrhosis, liver failure, or haemolysis represent a group with advanced hepatic involvement. Chelating agents are a primary therapeutic consideration in this setting.

Previous Treatment — Targets Not Achieved

Prior therapy: Switching the chelating agent — D-penicillamine to trientine, or trientine to D-penicillamine
Goals that were not reached: Resolution of jaundice and ascites; improvement or normalisation of liver parameters (ALT, INR, albumin); 24-hour urinary copper excretion within the maintenance target range

Failure to reach these targets is the indication for escalation to the next line of management.

Next-Step Approach

Liver transplantation may be considered as the next therapeutic step in this setting. Full clinical criteria and patient selection details are in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2024.11.007

Chelators should be the primary choice in patients with significant liver disease, e.g. features of significant fibrosis and cirrhosis, liver failure, and haemolysis (LoE 3, strong recommendation, strong consensus).

LT should be considered in patients with decompensated cirrhosis despite adequate medical treatment (LoE 2, strong recommendation, strong consensus).

View source ↗